Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: A multicenter study

Movement Disorders

Volumn 23, Issue 8, 2008, Pages 1130-1136

  García Ruiz, Pedro J ^a   Ignacio, Ángel Sesar ^b   Pensado, Begoña Ares ^b   García, Alfonso Castro ^b   Frech, Fernando Alonso ^c   López, Mercedes Álvarez ^d   González, José Arbelo ^e   Octavio, Joan Baiges ^f   Burguera Hernández, Juan Andrés ^g   Garriga, Matilde Calopa ^h   Blanco, Dulce Campos ⁱ   García, Belén Castaño ^j   Cordero, Manuel Carballo ^k   Peña, José Chacón ^d   Ibáñez, Anna Espino ^l   Onisalde, Aránzazu Gorospe ^m   Giménez Roldán, Santiago ^j   Ibáñez, Pilar Granés ⁿ   Vara, Jorge Hernández ^o   Alonso, Ramón Ibáñez ^p   Jiménez Jiménez, Félix Javier ^q   Krupinski, Jerzy ^h   Bojarsky, Jaime Kulisevsky ^r   Ramírez, Inés Legarda ^m   García, Elena Lezcano ^s   Martínez Castrillo, Juan Carlos ^t   González, Dolores Mateo ^j   Rodríguez, Francesc Miquel ^o   Rivera, Pablo Mir ^k   Fargas, Elena Munñoz ^f   Inchausti, José Obeso ^u   Romero, Jesús Olivares ^v   Plana, José Olivé ^w   Vallejo, Pilar Otermin ^x   Sedano, Berta Pascual ^r   de Colosía Rama, Víctor Pérez ^y   López Fraile, Isabel Pérez ^z   Comes, Albert Planas ^aa   Periz, Víctor Puente ^ab   Rodríguez Oroz, María Cruz ^u   García, Dolores Sevillano ^ac   Pérez, Pilar Solís ^ad   Muñoz, José Suárez ^ae   Gamo, Julia Vaamonde ^p   Merino, Caridad Valero ^af   Serra, Francesc Valldeoriola ^ag   Velázquez Pérez, José Miguel ^ah   Baña, Rosa Yáñez ^ai   Capdepon, Ivana Zamarbide ^a   more..

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^b Instituto de Salud Carlos III   (Spain)

^c HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^e HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

^f HOSPITAL VERGE DE LA CINTA   (Spain)

^g HOSPITAL UNIVERSITARIO LA FE   (Spain)

^h HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

ⁱ HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^j HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^k HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^l HOSPITAL SON LLÀTZER   (Spain)

^m HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

ⁿ HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^o HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^p HOSPITAL GENERAL UNIVERSITARIO DE CIUDAD REAL   (Spain)

^q HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^r HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^s HOSPITAL DE CRUCES   (Spain)

^t HOSPITAL RAMÓN Y CAJAL   (Spain)

^u UNIVERSITY CLINIC OF NAVARRA   (Spain)

^v Unidad de Salud Mental Comunitaria   (Spain)

^w HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^x HOSPITAL GENERAL DE GRANOLLERS   (Spain)

^y Hospital de Merida   (Spain)

^z HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^aa Hospital Municipal de Badalona   (Spain)

^ab HOSPITAL DEL MAR   (Spain)

^ac HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^ad HOSPITAL VIRGEN DE LOS LIRIOS   (Spain)

^ae Hospital Universitario de Gran Canaria Dr   (Spain)

^af HOSPITAL ARNAU DE VILANOVA   (Spain)

^ag HOSPITAL CLÍNIC   (Spain)

^ah HOSPITAL VIRGEN DE LA SALUD   (Spain)

^ai Nephrology Department   (Spain)

more..

Author keywords

Apomorphine; Levodopa induced dyskinesias; Motor fluctuations; Parkinson's disease; Subcutaneous infusion

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; APOMORPHINE; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOMPERIDONE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE OXIDASE INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONFUSION; CONTINUOUS INFUSION; DISEASE DURATION; DISEASE SEVERITY; DROWSINESS; DRUG EFFICACY; DRUG TOLERABILITY; DYSKINESIA; FEMALE; FOLLOW UP; HALLUCINATION; HEMOLYTIC ANEMIA; HUMAN; HYPERSEXUALITY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MOTOR DYSFUNCTION; MULTICENTER STUDY; NAUSEA; ORTHOSTATIC HYPOTENSION; PANNICULITIS; PARKINSON DISEASE; PRIORITY JOURNAL; SEDATION; SIDE EFFECT; SKIN NODULE; UNIFIED PARKINSON DISEASE RATING SCALE; UNSPECIFIED SIDE EFFECT;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; APOMORPHINE; FEMALE; FOLLOW-UP STUDIES; GAIT; HUMANS; INFUSION PUMPS; LONG-TERM CARE; MALE; MIDDLE AGED; MOTOR ACTIVITY; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; TREATMENT OUTCOME;

EID: 52649108045     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22063     Document Type: Article

References (38)

1. Schwab RS, Amador LV, Lettvin JY. Apomorphine in Parkinson's disease. Trans Am Med Assoc 1951;56:251-253.
2. Cotzias GC, Papavasiliou PS, Fehling C, Kaufman B, Mena I. Similarities between neurologic effects of L-dopa and of apomorphine. N Engl J Med 1970;282:31-33.
3. Kempster PA, Frankel JP, Stern GM, Lees AJ. Comparison of motor response to apomorphine and levodopa in Parkinson's disease. J Neurol Neurosurg Psychiatry 1990;53:1004-1007.
4. Colosimo C, Merello M, Hughes AJ, Sieradzan K, Lees AJ. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon. J Neurol Neurosurg Psychiatry 1996;60:634-637.
5. Rossi P, Colosimo C, Moro E, Tonali P, Albanese A. Acute challenge with apomorphine and levodopa in Parkinsonism. Eur Neurol 2000;43:95-101.
6. Frankel JP, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 1990;53:96-101.
7. Pietz K, Hagell P, Odin P. Subcutaneous apomorphine in late stage Parkinson's disease: a long-term follow-up. J Neurol Neurosurg Psychiatry 1998;65:709-716.
8. Hughes AJ, Bishop S, Kleedorfer B, et al. Subcutaneous apomorphine in Parkinson's disease; response to chronic administration for up to 5 years. Mov Disord 1993;6:165-170.
9. Colzi A, Turner K, Lees AJ. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa-induced interdose dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998;64:573-576.
10. Stibe CM, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in parkinsonian on-off oscillations Lancet 1988;1:403-406.
11. Stocchi F, Bramante L, Monge A, et al. Apomorphine and lisuride infusion. A comparative long-term study. Adv Neurol 1993; 60:653-655.
12. Poewe W, Kleedorfer B, Wagner M, Bösch S, Schelosky L. Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease. Long-term follow-up in 18 patients. Adv Neurol 1993;60:656-659.
13. Wenning GK, Bösch S, Luginger E, et al. Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson's disease. Adv Neurol 1999;80: 545-548.
14. Stocchi F, Vacca L, De Pandis MF, Barbato L, Valente M, Ruggieri S. Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results. Neurol Sci 2001;22:93-94.
15. Kanovský P, Kubová D, Bares M, et al. Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up. Mov Disord 2002;17: 188-191.
16. Manson AJ, Turner K, Lees AJ. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients. Mov Disord 2002;17:1235-1241.
17. Chaudhuri KR, Critchley P, Abbott RJ, Pye IF, Millac PA. Subcutaneous apomorphine for on-off oscillations in Parkinson's disease. Lancet 1988;2:1260.
18. Pollak P, Champay AS, Gain JM, Hommel M, Benabid AL, Perret J. Subcutaneous administration of apomorphine in motor fluctuations in Parkinson's disease. Rev Neurol (Paris) 1990;146: 116-122.
19. Kreczy-Kleedorfer B, Wagner M, Bösch S, Poewe W. Long-term results of continuous subcutaneous apomorphine pump therapy in patients with advanced Parkinson disease. Nervenarzt 1993;64: 221-225.
20. Gancher ST, Nutt JG, Woodward WR. Apomorphine infusional therapy in Parkinson's disease: clinical utility and lack of tolerance. Mov Disord 1995;10:37-43.
21. Morgante L, Basile G, Epifanio A, et al. Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: a follow-up of two years. Arch Gerontol Geriatr Suppl 2004;9:291-296.
22. Tyne HL, Parsons J, Sinnott A, Fox SH, Fletcher NA, Steiger MJ. A 10 year retrospective audit of long-term apomorphine use in Parkinson's disease. J Neurol 2004;251:1370-1374.
23. Katzenschlager R, Hughes A, Evans A, et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov Disord 2005;20:151-157.
24. De Gaspari D, Siri C, Landi A, et al. Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. J Neurol Neurosurg Psychiatry 2006;77:450-453.
25. Ellis C, Lemmens G, Parkes JD, et al. Use of apomorphine in Parkinsonian patients with neuropsychiatric complications to oral treatment. Parkinsonism Relat Disord 1997;3:103-107.
26. Poewe W, Wenning GK. Apomorphine: an underutilized therapy for Parkinson's disease. Mot Disord 2000;25:789-794.
27. Deleu D, Hanssens Y, Northway MG. Subcutaneous apomorphine: an evidence-based review of its use in Parkinson's disease. Drugs Aging 2004;21:687-709.
28. Van Laar T, Jansen EN, Essink AW, Neef C, Oosterloo S, Roos RA. A double-blind study of the efficacy of apomorphine and its assessment in 'off'-periods in Parkinson's disease. Clin Neurol Neurosurg 1993;95:231-235.
29. Ostergaard L, Werdelin L, Odin P, et al. Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1995;58:681-687.
30. Dewey RB, Hutton JT, LeWitt PA, Factor SA. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 2001;58:1385-1392.
31. Pfeiffer RF, Gutmann L, Hull KL, Bottini PB, Sherry JH; APO302 Study Investigators. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson's disease. Parkinsonism Relat Disord 2007;13:93-100.
32. Koller W. How accurately can Parkinson's disease be diagnosed? Neurology 1992;42 (Suppl 1):6-16.
33. Lang AE, Fahn S. Assessment of Parkinson's disease. In: Munsat TL, editor. Quantification of neurological deficit. Boston, MA: Butterworth-Heinemann; 1989. p 285-309.
34. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003;60:387-392.
35. Alegret M, Valldeoriola F, Martí M, et al. Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson's disease. Mov Disord 2004;19:1463-1469.
36. Krack P, Batir A, Van Blercom N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 2003;349:1925-1934.
37. Rodriguez-Oroz MC, Zamarbide I, Guridi J, Palmero MR, Obeso JA. Efficacy of deep brain stimulation of the subthalamic nucleus in Parkinson's disease 4 years after surgery: double-blind and open-label evaluation. J Neurol Neurosurg Psychiatry 2004;75: 1382-1385.
38. Garcia Ruiz PJ, Muñiz de Igneson J, Ayerbe J, et al. Evaluation of timed tests in advanced parkinsonian patients candidates for subthalamic stimulation. Clin Neuropharmacol 2005;28:15-17.